| 1. |
Noguchi M, Moriya F, Suekane S, Matsuoka K, Arai G, Matsueda S, Sasada T, Yamada A, Itoh K. Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy. Prostate. 2011 Sep 19. doi: 10.1002/pros.21485. [Epub ahead of print] |
| 2. |
Komatsu N, Matsueda S, Tashiro K, Ioji T, Shichijo S, Noguchi M, Yamada A, Doi A, Suekane S, Moriya F, Matsuoka K, Kuhara S, Itoh K, Sasada T. Gene expression profiles in peripheral blood as a biomarker in cancer patients receiving peptide vaccination. Cancer. 2011 Nov 9. doi: 10.1002/cncr.26636. [Epub ahead of print] |
| 3. |
Noguchi M, Uemura H, Naito N, Akaza H, Yamada A, Itoh K. A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer. Prostate. 2011 Apr;71(5):470-9. doi: 10.1002/pros.21261. Epub 2010 Sep 28. |
| 4. |
Terasaki M, Shibui S, Narita Y, Fujimaki T, Aoki T, Kajiwara K, Sawamura Y, Kurisu K, Mineta T, Yamada A, Itoh K. Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme. J Clin Oncol. 2011 Jan 20;29(3):337-44. Epub 2010 Dec 13. |
| 5. |
Noguchi M, Mine T, Komatsu N, Suekane S, Moriya F, Matsuoka K, Yutani S, Shichijo S, Yamada A, Toh U, Kawano K, Azuma K, Uemura H, Okuno K, Matsumoto K, Yanagimoto H, Yamanaka R, Oka M, Todo S, Sasada T, Itoh K. Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. Cancer Biol Ther. 2011 Jan 12;10(12):1266-79. Epub 2010 Dec 15. |
| 6. |
Yoshida K, Noguchi M, Mine T, Komatsu N, Yutani S, Ueno T, Yanagimoto H, Kawano K, Itoh K, and Yamada A. Characteristics of severe adverse events after peptide vaccination for advanced cancer patients: analysis of 500 cases. Oncol Rep. 2011 Jan;25(1):57-62. |
| 7. |
Yamada A, Noguchi M, Komatsu N, Suekane S, Yutani S, Moriya F, Mine T, Momozono K, Kawano K, Itoh K. Phase I clinical study of a personalized peptide vaccination available for six different human leukocyte antigen (HLA-A2, -A3, -A11, -A24, -A31 and -A33)-positive patients with advanced cancer. Exp Ther. Med. 2: 109-117, 2011. |
| 8. |
Komatsu N, Yutani S, Yamada A, Shichijo S, Yoshida K, Itou M, Kuromatsu R, Ide T, Tanaka M, Sata M, and Itoh K. Prophylactic effect of peptide vaccination against hepatocellular carcinoma associated with hepatitis C virus. Experimental and Therapeutic Medicine. 2010; 1(4):619-626. |
| 9. |
Komatsu N, Terasaki Y, Moriya F, Suekane S, Noguchi M, Todo S, Itoh K, and Shichijo S. A ?-tubulin 5-derived peptide can induce CTLs restricted to the HLA -A24 allele in prostate cancer patients. Experimental and Therapeutic Medicine. 2010,1：833-839. |
| 10. |
Matsumoto K, Noguchi M, Satoh T, Tabata KI, Fujita T, Iwamura M, Yamada A, Komatsu N, Baba S, Itoh K. A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin. BJU Int. 2010 Dec 16. doi: 10.1111/j.1464-410X.2010.09933.x. [Epub ahead of print] |
| 11. |
Iseki K, Matsunaga H, Komatsu N, Suekane S, Noguchi M, Itoh K, Yamada A. Evaluation of a new oil adjuvant for use in peptide-based cancer vaccination. Cancer Sci. 2010 Oct;101(10):2110-4. doi: 10.1111/j.1349-7006.2010.01653.x. Epub 2010 Jul 30. |
| 12. |
Yanagimoto H, Shiomi H, Satoi S, Mine T, Toyokawa H, Yamamoto T, Tani T, Yamada A, Kwon A, Komatsu N, Itoh K, Noguchi M. A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. Oncology Reports 2010, 24:795-801. |
| 13. |
Noguchi M, Kakuma T, Uemura H, Nasu Y, Kumon H, Hirao Y, Moriya F, Suekane S, Matsuoka K, Komatsu N, Shichijo S, Yamada A, Itoh K. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother. 2010 Jul;59(7):1001-9. Epub 2010 Feb 10. |
| 14. |
Uemura H, Fujimoto K, Mine T, Uejima S, De Velasco MA, Hirao Y, Komatsu N, Yamada A, Itoh K. Immunological evaluation of personalized peptide vaccination monotherapy in patients with castration-resistant prostate cancer. Cancer Sci 2010, 101:601-608 |
| 15. |
Niu Y, Terasaki Y, Komatsu N, Noguchi M, Shichijo S, Itoh K. Identification of peptides applicable as vaccines for HLA-A26-positive cancer patients. Cancer Sci. 2009 Nov;100(11):2167-74. Epub 2009 Jul 23. |
| 16. |
Yutani S, Komatsu N, Shichijo S, Yoshida K, Takedatsu H, Itou M, Kuromatu R, Ide T, Tanaka M, Sata M, Yamada A, Itoh K. Phase I clinical study of a peptide vaccination for hepatitis C virus-infected patients with different human leukocyte antigen-class I-A alleles. Cancer Sci. 2009 Oct;100(10):1935-42. Epub 2009 Jun 23. |
| 17. |
Niu Y, Komatsu N, Komohara Y, Matsueda S, Yutani S, Ishihara Y, Itou M, Yamada A, Itoh K, Shichijo S. A peptide derived from hepatitis C virus (HCV) core protein inducing cellular responses in patients with HCV with various HLA class IA alleles. J Med Virol. 2009 Jul;81(7):1232-40. |
| 18. |
Terasaki Y, Shichijo S, Niu Y, Komatsu N, Noguchi M, Todo S, Itoh K. An HLA-A3-binding prostate acid phosphatase-derived peptide can induce CTLs restricted to HLA-A2 and -A24 alleles. Cancer Immunol Immunother. 2009 Nov;58(11):1877-85. Epub 2009 Mar 28. |
| 19. |
Mohamed ER, Naito M, Terasaki Y, Niu Y, Gohara S, Komatsu N, Shichijo S, Itoh K, Noguchi M. Capability of SART3(109-118) peptide to induce cytotoxic T lymphocytes from prostate cancer patients with HLA class I-A11, -A31 and -A33 alleles. Int J Oncol. 2009 Feb;34(2):529-36. |
| 20. |
Komatsu N, Harada M, Nakagawa M, Tanaka Y, Ono T, Gohara S, Ohkubo K, Itoh K. A correlation between symptom severity and unbalanced reactive IgA production in Japanese cedar pollinosis patients. Asian Pac J Allergy Immunol. 2008 Jun-Sep;26(2-3):97-104. |
| 21. |
Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, Aizawa H. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer. 2009 Jun;64(3):326-33. Epub 2008 Nov 1. |
| 22. |
Gohara S, Shichijo S, Komatsu N, Okuda S, Yutani S, Itoh K. Detection of IgE antibody specific to a hepatitis C virus-derived peptide being recognized by cellular immunity in patients with HCV infection. Viral Immunol. 2008 Sep;21(3):365-9. |
| 23. |
Naito M, Itoh K, Komatsu N, Yamashita Y, Shirakusa T, Yamada A, Moriya F, Ayatuka H, Mohamed ER, Matsuoka K, Noguchi M. Dexamethasone did not suppress immune boosting by personalized peptide vaccination for advanced prostate cancer patients. Prostate. 2008 Dec 1;68(16):1753-62. |
| 24. |
Jin M, Komohara Y, Shichijo S, Yamanaka R, Nikawa J, Itoh K, Yamada A. Erythropoietin-producing hepatocyte B6 variant-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ glioma patients. Cancer Sci. 2008 Aug;99(8):1656-62. |
| 25. |
Jin M, Komohara Y, Shichijo S, Harada M, Yamanaka R, Miyamoto S, Nikawa J, Itoh K, Yamada A. Identification of EphB6 variant-derived epitope peptides recognized by cytotoxic T-lymphocytes from HLA-A24+ malignant glioma patients. Oncol Rep. 2008 May;19(5):1277-83. |
| 26. |
Noguchi M, Kakuma T, Tomiyasu K, Yamada A, Itoh K, Konishi F, Kumamoto S, Shimizu K, Kondo R, Matsuoka K. Randomized clinical trial of an ethanol extract of Ganoderma lucidum in men with lower urinary tract symptoms. Asian J Androl. 2008 Sep;10(5):777-85. Epub 2007 Dec 20. |
| 27. |
Naito M, Komohara Y, Ishihara Y, Noguchi M, Yamashita Y, Shirakusa T, Yamada A, Itoh K, Harada M. Identification of Lck-derived peptides applicable to anti-cancer vaccine for patients with human leukocyte antigen-A3 supertype alleles. Br J Cancer. 2007 Dec 17;97(12):1648-54. Epub 2007 Nov 27. |
| 28. |
Komohara Y, Harada M, Ishihara Y, Suekane S, Noguchi M, Yamada A, Matsuoka K, Itoh K. HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma. Oncol Rep. 2007 Dec;18(6):1463-8. |
| 29. |
Suekane S, Nishitani M, Noguchi M, Komohara Y, Kokubu T, Naitoh M, Honma S, Yamada A, Itoh K, Matsuoka K, Kanayama H. Phase I trial of personalized peptide vaccination for cytokine-refractory metastatic renal cell carcinoma patients. Cancer Sci. 2007 Dec;98(12):1965-8. Epub 2007 Oct 5. |
| 30. |
Itoh Y, Komohara Y, Komatsu N, Minami T, Saito K, Noguchi M, Itoh K, Harada M. New peptides of the polycomb group protein enhancer of zeste homolog 2 with the potential to induce cancer-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ prostate cancer patients. Oncol Rep. 2007 Nov;18(5):1231-7. |
| 31. |
Yutani S, Yamada A, Yoshida K, Takao Y, Tamura M, Komatsu N, Ide T, Tanaka M, Sata M, Itoh K. Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy. Vaccine. 2007 Oct 16;25(42):7429-35. Epub 2007 Aug 24. |
| 32. |
Azuma K, Komohara Y, Sasada T, Terazaki Y, Ikeda J, Hoshino T, Itoh K, Yamada A, Aizawa H. Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci. 2007 Sep;98(9):1336-43. Epub 2007 Jul 19. |
| 33. |
Homma S, Komohara Y, Harada M, Saya H, Todo S, Itoh K, Noguchi M. Differential levels of human leukocyte antigen-class I, multidrug-resistance 1 and androgen receptor expressions in untreated prostate cancer cells: the robustness of prostate cancer. Oncol Rep. 2007 Aug;18(2):343-6. |
| 34. |
Takao Y, Yamada A, Yutani S, Ono T, Nagao Y, Ando E, Ide T, Itoh K, Sata M. Serum levels of IgG to the peptide of HCV1b core at positions 35-44 correlated with persistent infection, while levels of IgG to the peptide of NS5A at positions 2132-2140 correlated with better prognosis in HCV-infected patients. Med Microbiol Immunol. 2007 Sep;196(3):157-64. Epub 2007 Feb 16. |
| 35. |
Tanaka M, Komatsu N, Terakawa N, Yanagimoto Y, Oka M, Sasada T, Mine T, Gouhara S, Shichijo S, Okuda S, Itoh K. Increased levels of IgG antibodies against peptides of the prostate stem cell antigen in the plasma of pancreatic cancer patients. Oncol Rep. 2007 Jul;18(1):161-6. |
| 36. |
Noguchi M, Mine T, Yamada A, Obata Y, Yoshida K, Mizoguchi J, Harada M, Suekane S, Itoh K, Matsuoka K. Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: an analysis of prognostic factors in the treatment. Oncol Res. 2007;16(7):341-9. |
| 37. |
Noguchi M, Yao A, Harada M, Nakashima O, Komohara Y, Yamada S, Itoh K, Matsuoka K. Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer. Prostate. 2007 Jun 15;67(9):933-42. |
| 38. |
Takao Y, Yamada A, Yutani S, Takedatsu H, Ono T, Etoh K, Wang Y, Suzuki S, Ide T, Shimotohno K, Sata M, Itoh K. Identification of new immunogenic peptides in conserved regions of hepatitis C virus (HCV) 1b with the potentiality to generate cytotoxic T lymphocytes in HCV1b(+) HLA-A24(+) patients. Hepatol Res. 2007 Mar;37(3):186-95. |
